financingeXmoor Pharma Ltd raises US$35mBristol-based eXmoor Pharma Ltd has completed a US$35m Series A financing to expand its cell and gene therapy manufacturing capabilities. more ➔
financingVarmX BV raises €30m in Series B2 financ...Leiden-based VarmX BV said it will use the €30m Series B2 money to complete the data required for IND approval of its lead candidate VMX-C001, a recombinante antidote to oral factor Xa inhibitors which … more ➔
immunoncologyGlioma drug combo turns tumours hotAn anti-TNF-antibody-cytokine fusion combo with chemotherapy turns inoperable brain tumours hot in mice. A Phase I trial sponsored by Philogen SpA is underway. more ➔
M&AVectivBio taken over in $1bn acquisitionGI specialist Ironwood Pharmaceuticals Inc. has announced to acquire Swiss VectivBio Holding AG for $17 per share in an all-cash transaction. more ➔
AIAI predicts an enzymes substrateA new machine learning model can predict enzyme-substrate pairs, with an accuracy of over 90% and is ready to be used in pharmaceutical and industrial biotechnology. more ➔
decarbonisationLanzaTech and Plastipak produce greener PE...Carbon-capture specialist LanzaTech Global and Plastipak Packaging Inc have produced the worlds first PET resin made from captured carbon emissions. more ➔
Multiple sclerosisRoches meets endpoints in relapsing mult...Roche’s brutons tyrosine kinas blocker fenebrutinib has met all endpoints in proof-of-concept study with patients suffering from relapsing-remitting multiple sclerosis. more ➔
CGTuniQure sells royalty interest in gene the...uniQure N.V. is to sell a portion of its royalty rights from the net sales o its hemophilia B gene therapy etranacogene dezaparvovec-drbl to HealthCare Royalty and Sagard Healthcare for a gross purchase … more ➔
financingDualyx NV raises €40m in Series A financ... Belgian T reg specialist Dualyx NV had raised €40m to progress its three preclinical Treg candidates for autoimmune diseases into the clinic. more ➔
RSVSanofi’s/Astazeneca’s anti-RSV...NHS research partners of AstraZeneca and Sanofi have reported a 83% reduction in RSV infant hospitalisations in a post-approval clinical trial. more ➔
